Investigator Initiated Innovation in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 16, 2026
Can you apply?
This grant is for early-stage exploratory research in computational genomics and data science. Eligible applicants include independent investigators, postdoctoral researchers, graduate students, and faculty at academic institutions, national laboratories, small businesses, and other research organizations. Applicants must propose original, pilot-stage research that does not involve clinical trials. Geographic scope is U.S.-based institutions and researchers. The R21 mechanism supports high-risk, high-reward investigations that generate preliminary data for future R01 applications. Activities supported include computational method development, genomic data analysis infrastructure, algorithm innovation, and feasibility studies in data science applications to biomedical research.
Not the right fit? Find grants for your organization in 5 questions →
Program description
The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research developing innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems. All applications should address how the methods would scale to address increasingly larger data sets.
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- City / Municipal Government
- County Government
- Graduate Student
- Nonprofits
- Postdoctoral Researcher
- Private University
- Public Authority
- Public K-12 School
- Public University
- Researcher (independent)
- Small Business (SBA-defined)
- Special District
- State Government
- Tribal Nation
- Tribal Organization
How to apply
Application links
Required documents
- NIH Application Form (SF-424 R&R)
- Project Narrative/Research Strategy (max. 6 pages for R21)
- Specific Aims page (typically 1 page)
- Preliminary Studies/Progress Report section
- Research Design and Methods
- Budget and Budget Justification (Form PHS 398)
- Biographical Sketches (NIH format) for all senior key personnel
- Resources and Environment description
- Letters of Support or Collaboration Agreements (if applicable)
- Data Management Plan (increasingly required by NIH)
- No Clinical Trial Certification (if applicable)
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.172 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$39,531,110
-
$34,574,245
-
$32,186,204
-
$30,195,606
-
$26,495,937
-
$26,020,371
-
$24,964,130
-
$24,413,854
-
$23,757,911
-
$22,977,417
Top States by Funding
- CA 19 awards $317.2M
- MA 16 awards $302.5M
- WA 9 awards $140.1M
- NY 6 awards $93.6M
- NC 5 awards $93.0M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.172). How funding has trended year over year.
| 2024 | $452,727,668 | |
| 2025 | $423,878,429 | |
| 2026 est. | $9,989,158 |
FAQ
Who is eligible to apply for this R21 grant?
Individuals with a doctoral degree (PhD, MD, DO, DVM, DDS, or equivalent) from domestic or foreign institutions, including early-career investigators, postdocs, and faculty. Eligible institutions include universities, medical schools, hospitals, research organizations, and small businesses. Clinical trials are not permitted under this mechanism.
What is the typical funding amount and project duration?
R21 grants typically provide $275,000–$500,000 in direct costs over 2 years. Actual amounts vary; check the FOA for current guidance.
What types of research activities are supported?
Computational genomics method development, data science algorithm innovation, infrastructure development, feasibility studies, and preliminary investigations. Clinical trials, large-scale clinical studies, and routine data analysis are not allowed.
When are the application deadlines?
Standard NIH deadlines typically occur in February, June, and October each year. Check the specific FOA for exact dates, as they may shift.
How competitive is this funding?
R21 mechanisms are moderately competitive. Success rates typically range from 15–25%. Strong preliminary data, clear innovation in computational methods, and feasibility demonstration are important for competitiveness.
💡 Tips for applicants
- Emphasize the novel computational or data science innovation: explain how your methods differ from existing approaches and why the early-stage funding is appropriate to test feasibility.
- Include preliminary data or proof-of-concept results demonstrating the method works at a small scale or in model systems; this significantly strengthens R21 applications.
- Clearly delineate the scope as pilot or feasibility work; explain how results will support a future R01 or larger grant application.
- Ensure your research team includes expertise in both computational science and the relevant biomedical domain; interdisciplinary collaboration is highly valued.
- Address reproducibility and data management upfront—describe how code, algorithms, and results will be documented, validated, and made available to the research community.
⚠️ Common mistakes
Applicants frequently underestimate the importance of preliminary data in R21 submissions; reviewers need to see proof-of-concept or feasibility evidence early, not vague promises of future validation. Another common pitfall is framing the project as a traditional clinical trial or large-scale study; R21 supports exploratory, pilot-stage work only, so overselling the scale or maturity of the research leads to rejection. Finally, weak computational methods justification—not explaining why the new approach is innovative or what specific computational problem you're solving—makes proposals appear incremental rather than truly innovative.
Similar grants
- OPEN Investigator Initiated Innovation in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional) — National Institutes of Health
- OPEN Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Supporting Talented Early Career Researchers in Genomics (R01 Clinical Trial Optional) — National Institutes of Health
- OPEN Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed) — National Institutes of Health